Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Astellas opens new Japanese research facilities

This article was originally published in Scrip

Executive Summary

Astellashas inaugurated several new facilities at its existing research site in Tsukuba, Japan. The three laboratories, office and other facilities total 85,000m2, more than doubling the floor area at the campus, and cost ¥30 billion ($286.3 million) to build. All Japanese discovery functions, including in the pharmacology and chemistry areas, will be transferred to the site next spring. The move is part of a wider restructuring of domestic R&D facilities which will see the closure of a Tokyo research centre and the concentration of development research at the Kashima site near Osaka. Astellas has also dissolved its Fujisawa Ireland subsidiary in Killorglin, Ireland, following the transfer of all functions to Astellas Ireland, its main European production operation set up in 2005.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC027633

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel